Get access to our best features
Get access to our best features
Published 1 year ago

Health News Roundup: Merck could keep its patent edge by shifting Keytruda cancer drug to a simple shot; Pfizer to invest more than $2.5 billion to expand European manufacturing and more

Summary by Ground News
Merck could keep its patent edge by shifting Keytruda cancer drug to a simple shot. Pfizer to invest more than $2.5 billion at its drug making plants in Belgium and Ireland. Mpox expected to no longer be considered a public health emergency in the United States from 2023.

0 Articles

All
Left
Center
Right
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe
Ground News Article Assistant
Not enough coverage to generate an Article Assistant.

Bias Distribution

  • 50% of the sources are Center, 50% of the sources lean Right
50% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)